Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00087594
Status:
COMPLETED
Last Update Posted:
2016-03-04
First Post:
2004-07-12
Brief Title:
A Study of PEGASYS Peginterferon Alfa-2a 40KD in Combination With Copegus Ribavirin in Patients With Chronic Hepatitis C CHC Enrolled in a Methadone Maintenance Treatment Program
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
An Open-Label Multi-Center Randomized Safety Feasibility and Tolerability Pilot Study of Pegasys Peginterferon Alfa-2a Plus Copegus Ribavirin in Previous Intravenous Drug Users Who Are Currently Enrolled in a Methadone Maintenance Treatment Program
Status:
COMPLETED
Status Verified Date:
2016-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the safety and tolerability of PEGASYS plus ribavirin in previous intravenous iv drug users who have CHC and are currently enrolled in a methadone maintenance treatment program The anticipated time on study treatment is 1-2 years and the target sample size is 100 individuals
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None